bronchiolitis obliterans syndrome epidemiology forecast insight

DelveInsight’s ‘Bronchiolitis Obliterans Syndrome – Epidemiology Forecast – 2034’ report delivers an in-depth understanding of the historical and forecasted epidemiology of Bronchiolitis Obliterans Syndrome in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2021-2034

Bronchiolitis Obliterans Syndrome: Disease Understanding

Bronchiolitis Obliterans Syndrome Overview

According to the Genetic and Rare Diseases Information Center (GARD), Bronchiolitis Obliterans Syndrome (BOS) is an inflammatory condition that affects the lung’s tiniest airways, the bronchioles. The bronchioles may become damaged and inflamed in affected people, leading to extensive scarring that blocks the airways. Many different chemicals (such as nitrogen oxides, ammonia, welding fumes, or food flavoring fumes) and respiratory infections can cause lung injury, leading to bronchiolitis obliterans. It can also be associated with rheumatoid arthritis and graft-versus-host disease following a lung or hematopoietic cell transplantation.

The most common symptoms include shortness of breath, dry cough, and sometimes wheezing and fatigue in the absence of a cold or asthma. Symptoms will normally develop over a few weeks or months and flare up while exercising or manual labor. Depending on the exposure, other parts of the body may experience irritation. For example, a skin rash may develop in addition to respiratory problems. As the condition progresses, symptoms will worsen.

Bronchiolitis Obliterans may result from lung injury caused by a variety of different chemicals and respiratory infections. Inhaled chemicals known to irritate the lungs and lead to the condition include chlorine, ammonia, oxides of nitrogen or sulfur dioxide, welding fumes, or food flavoring fumes (such as diacetyl). In addition, respiratory infections caused by a respiratory syncytial virus, adenovirus, or Mycoplasma pneumonia have been linked with the condition.

A diagnosis of Bronchiolitis Obliterans is often suspected based on the presence of characteristic signs and symptoms. Additional testing can then be ordered to support and confirm the diagnosis. These tests may include imaging studies (such as a chest CT scan), pulmonary function tests, and surgical lung biopsy.

The best treatment options and the effectiveness of the selected treatments vary based on the underlying cause and the severity of the condition. Medications often prescribed to people with Bronchiolitis Obliterans include certain antibiotics (called macrolide antibiotics), corticosteroids, and immunosuppressive drugs.

The combination of budesonide/formoterol, montelukast, and n-acetylcysteine significantly improved lung function and respiratory symptoms in patients with Bronchiolitis Obliterans Syndrome after allogeneic HSCT. Furthermore, combination therapy showed a better therapeutic response in patients with Bronchiolitis Obliterans Syndrome who showed prominent lung function decreases between pre-HSCT and Bronchiolitis Obliterans Syndrome diagnosis.

Bronchiolitis Obliterans Syndrome: Epidemiology

The Bronchiolitis Obliterans Syndrome epidemiology division provides insights into the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, trends, and assumptions.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Bronchiolitis Obliterans Syndrome epidemiology segmented as Incident cases of Lung Transplant, Incident cases of Hematopoietic Stem Cell Transplant, Diagnosed prevalence of Bronchiolitis Obliterans Syndrome after Lung Transplant, Diagnosed prevalence of Bronchiolitis Obliterans Syndrome after Hematopoietic Stem Cell Transplants and Grade-wise Bronchiolitis Obliterans Syndrome cases. The report includes the prevalent scenario of Bronchiolitis Obliterans Syndrome in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2021 to 2034.

Country-wise Bronchiolitis Obliterans Syndrome Epidemiology

The epidemiology segment also provides the Bronchiolitis Obliterans Syndrome epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total diagnosed prevalent population of Bronchiolitis Obliterans Syndrome in the 7MM countries was estimated to be 31,570 cases in 2020.

As per the estimates, the United States had the largest diagnosed prevalence of Bronchiolitis Obliterans Syndrome in 2020. Among the EU5 countries, Germany had the largest prevalent population of Bronchiolitis Obliterans Syndrome with 3,422 cases, followed by France in 2020. On the other hand, Spain had the lowest prevalent population of 1,653 cases in 2020.

Scope of the Report

• Bronchiolitis Obliterans Syndrome report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• Bronchiolitis Obliterans Syndrome Epidemiology Report and Model provide an overview of the risk factors and global Bronchiolitis Obliterans Syndrome trends in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report provides insight into the historical and forecasted patient pool of Bronchiolitis Obliterans Syndrome in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Bronchiolitis Obliterans Syndrome.
• The report provides the segmentation of the Bronchiolitis Obliterans Syndrome epidemiology by Incident cases of Lung Transplant of Bronchiolitis Obliterans Syndrome in the 7MM
• The report provides the segmentation of the Bronchiolitis Obliterans Syndrome epidemiology by Incident cases of Hematopoietic Stem Cell Transplant cases of Bronchiolitis Obliterans Syndrome in the 7MM.
• The report provides the segmentation of the Bronchiolitis Obliterans Syndrome epidemiology by the Diagnosed prevalence of Bronchiolitis Obliterans Syndrome after Lung Transplant in the 7MM
• The report provides the segmentation of the Bronchiolitis Obliterans Syndrome epidemiology by the Diagnosed prevalence of Bronchiolitis Obliterans Syndrome after Hematopoietic Stem Cell Transplant in the 7MM.
• The report provides the segmentation of the Bronchiolitis Obliterans Syndrome epidemiology by Grade-wise cases of Bronchiolitis Obliterans Syndrome in the 7MM.

Report Highlights

• 10-year Forecast of Bronchiolitis Obliterans Syndrome epidemiology.
• 7MM Coverage.
• Incident cases of Lung Transplant.
• Incident cases of Hematopoietic Stem Cell Transplant.
• Diagnosed prevalence of Bronchiolitis Obliterans Syndrome after Lung Transplant.
• Diagnosed prevalence of Bronchiolitis Obliterans Syndrome after Hematopoietic Stem Cell Transplants.
• Grade-wise Bronchiolitis Obliterans Syndrome cases.

KOL Views

We interview KOLs and obtain SME’s opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM for the patient population pertaining to Bronchiolitis Obliterans Syndrome?
• What are the key findings pertaining to the Bronchiolitis Obliterans Syndrome epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2021-2034)?
• What would be the total number of patients with Bronchiolitis Obliterans Syndrome across the 7MM during the forecast period (2021-2034)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2021-2034)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2021-2034)?
• What are the disease risk, burdens, and unmet needs of Bronchiolitis Obliterans Syndrome?
• What are the currently available treatments for Bronchiolitis Obliterans Syndrome?

Reasons to buy

Bronchiolitis Obliterans Syndrome Epidemiology report will allow the user to:

• Develop business strategies by understanding the trends shaping and driving the global Bronchiolitis Obliterans Syndrome market
• Quantify patient populations in the global Bronchiolitis Obliterans Syndrome market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Bronchiolitis Obliterans Syndrome therapeutics in each of the markets covered
• Understand the magnitude of the Bronchiolitis Obliterans Syndrome population by its Incident cases of Lung Transplant.
• Understand the magnitude of the Bronchiolitis Obliterans Syndrome population by its Incident cases of Hematopoietic Stem Cell Transplant.
• Understand the magnitude of the Bronchiolitis Obliterans Syndrome population by its Diagnosed prevalence of Bronchiolitis Obliterans Syndrome after Lung Transplant.
• Understand the magnitude of the Bronchiolitis Obliterans Syndrome population by its Diagnosed prevalence of Bronchiolitis Obliterans Syndrome after Hematopoietic Stem Cell Transplants.
• Understand the magnitude of the Bronchiolitis Obliterans Syndrome population by its Grade-wise Bronchiolitis Obliterans Syndrome cases 
• The Bronchiolitis Obliterans Syndrome epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The Bronchiolitis Obliterans Syndrome Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population